

# Shu-Feng Zhou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5049195/publications.pdf>

Version: 2024-02-01

421  
papers

27,684  
citations

7568

77  
h-index

7950

149  
g-index

422  
all docs

422  
docs citations

422  
times ranked

40738  
citing authors

#	ARTICLE	IF	CITATIONS
1	3D-Printed Aldo-keto reductase within biocompatible polymers as catalyst for chiral drug intermediate. <i>Chemical Engineering Journal</i> , 2022, 429, 132293.	12.7	10
2	3D printing of recombinant <i>Escherichia coli</i> /Au nanocomposites as agitating paddles towards robust catalytic reduction of 4-nitrophenol. <i>Journal of Hazardous Materials</i> , 2022, 423, 126983.	12.4	11
3	Convenient Immobilization of $\alpha$ -L-Rhamnosidase on Cerium-based Metal-Organic Frameworks Nanoparticles for Enhanced Enzymatic Activity and Recyclability. <i>ChemCatChem</i> , 2022, 14, .	3.7	4
4	Photoredox-catalyzed synthesis of sulfonated oxazolines from <i>N</i> -allylamides through the insertion of sulfur dioxide. <i>Organic Chemistry Frontiers</i> , 2022, 9, 364-369.	4.5	18
5	Cobalt Phthalocyanine Supported on Mesoporous $\text{CeO}_2$ as an Active Molecular Catalyst for CO Oxidation. <i>ACS Applied Materials &amp; Interfaces</i> , 2022, 14, 9151-9160.	8.0	9
6	Biocompatible 2D Cu-TCPP Nanosheets Derived from $\text{Cu}_2\text{O}$ Nanocubes as Multifunctional Nanoplatfoms for Combined Anticancer Therapy. <i>ACS Biomaterials Science and Engineering</i> , 2022, 8, 1074-1086.	5.2	11
7	Quorum Quenching Bacteria <i>Bacillus velezensis</i> DH82 on Biological Control of <i>Vibrio parahaemolyticus</i> for Sustainable Aquaculture of <i>Litopenaeus vannamei</i> . <i>Frontiers in Marine Science</i> , 2022, 9, .	2.5	3
8	CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma. <i>Aging</i> , 2022, 14, 4673-4698.	3.1	6
9	Enhancing the biocatalytic synthesis of chiral drug intermediate by rational design an aldo-keto reductase from <i>Bacillus megaterium</i> YC4-R4. <i>Enzyme and Microbial Technology</i> , 2022, 160, 110074.	3.2	5
10	Visible light-induced selenylative spirocyclization of biaryl ynones toward the formation of selenated spiro[5.5]trienones. <i>Organic and Biomolecular Chemistry</i> , 2022, 20, 5779-5783.	2.8	17
11	Confined growth of MOF nanocrystals using a "locked" metal ion source. <i>Journal of Materials Chemistry A</i> , 2021, 9, 3976-3984.	10.3	13
12	Enhanced targeting of 3D pancreatic cancer spheroids by aptamer-conjugated polymeric micelles with deep tumor penetration. <i>European Journal of Pharmacology</i> , 2021, 894, 173814.	3.5	21
13	Marine-Source Quorum Quenching Enzyme YtnP to Improve Hygiene Quality in Dental Units. <i>Marine Drugs</i> , 2021, 19, 225.	4.6	10
14	Inkjet printing-assisted single-cell microarray on a hydrophobic surface chip for real-time monitoring of enzyme kinetics at single-cell level. <i>Talanta</i> , 2021, 225, 122019.	5.5	11
15	The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells. <i>Scientific Reports</i> , 2021, 11, 10791.	3.3	28
16	Ni-Based Metal-Organic Framework Nanorods Self-assembled into Hollow Architecture and Decorated with Pt Nanoparticles as Nanocatalysts for CO Oxidation. <i>ACS Applied Nano Materials</i> , 2021, 4, 4356-4360.	5.0	7
17	Fabrication of Versatile Hollow Metal-Organic Framework Nanoplatfoms for Folate-Targeted and Combined Cancer Imaging and Therapy. <i>ACS Applied Bio Materials</i> , 2021, 4, 6417-6429.	4.6	17
18	Bovine extracellular vesicles contaminate human extracellular vesicles produced in cell culture conditioned medium when "exosome-depleted serum" is utilised. <i>Archives of Biochemistry and Biophysics</i> , 2021, 708, 108963.	3.0	18

#	ARTICLE	IF	CITATIONS
19	Simultaneously Enhanced Charge Separation and Transfer in Cocatalyst-Free Hematite Photoanode by Mo/Sn Codoping. <i>ACS Applied Energy Materials</i> , 2021, 4, 10368-10379.	5.1	16
20	Metal-Free Sulfonylative Spirocyclization of Indolyl-ynones via Insertion of Sulfur Dioxide: Access to Sulfonated Spiro[cyclopentenone-1,3 $\alpha^2$ -indoles]. <i>Organic Letters</i> , 2021, 23, 7992-7995.	4.6	29
21	Environmental occurrence, fate, impact, and potential solution of tire microplastics: Similarities and differences with tire wear particles. <i>Science of the Total Environment</i> , 2021, 795, 148902.	8.0	101
22	Facile Construction of Bio-Based Supramolecular Hydrogels from Dehydroabiatic Acid with a Tricyclic Hydrophenanthrene Skeleton and Stabilized Gel Emulsions. <i>Molecules</i> , 2021, 26, 6526.	3.8	7
23	3D-Printed metal-organic frameworks within biocompatible polymers as excellent adsorbents for organic dyes removal. <i>Journal of Hazardous Materials</i> , 2020, 384, 121418.	12.4	104
24	A novel dissolution-precipitation method for high efficiency separation of oil-wetted oil sands. <i>Canadian Journal of Chemical Engineering</i> , 2020, 98, 1157-1163.	1.7	2
25	Fabrication of Folic Acid-Decorated Hollow ZIF-8/Au/CuS Nanocomposites for Enhanced and Selective Anticancer Therapy. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 6095-6107.	5.2	25
26	Microfluidic-Integrated Multicolor Immunosensor for Visual Detection of HIV-1 p24 Antigen with the Naked Eye. <i>Analytical Chemistry</i> , 2020, 92, 11826-11833.	6.5	48
27	Investigating the Mechanisms of AquaporinZ Reconstitution through Polymeric Vesicle Composition for a Biomimetic Membrane. <i>Polymers</i> , 2020, 12, 1944.	4.5	2
28	The Effectiveness of Nafion-Coated Stainless Steel Surfaces for Inhibiting <i>Bacillus Subtilis</i> Biofilm Formation. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 5001.	2.5	4
29	Structural Isomerism of Two CeBTC for Fabricating Pt/CeO <sub>2</sub> Nanorods toward Low Temperature CO Oxidation. <i>Small</i> , 2020, 16, e2003597.	10.0	62
30	Synthesis of ZIF-8 Nanocrystals Mediated by CO <sub>2</sub> Gas Bubbling: Dissolution and Recrystallization. <i>Langmuir</i> , 2020, 36, 14306-14317.	3.5	5
31	Quorum Quenching Mediated Bacteria Interruption as a Probable Strategy for Drinking Water Treatment against Bacterial Pollution. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9539.	2.6	6
32	Biomimetic Au/CeO <sub>2</sub> Catalysts Decorated with Hemin or Ferrous Phthalocyanine for Improved CO Oxidation via Local Synergistic Effects. <i>IScience</i> , 2020, 23, 101852.	4.1	11
33	Characterization and Catalytic-Site-Analysis of an Aldo-Keto Reductase with Excellent Solvent Tolerance. <i>Catalysts</i> , 2020, 10, 1121.	3.5	8
34	Intercalation of laminar Cu-Al LDHs with molecular TCPP(M) (M = Zn, Co, Ni, and Fe) towards high-performance CO <sub>2</sub> hydrogenation catalysts. <i>Nanoscale</i> , 2020, 12, 13145-13156.	5.6	25
35	Improvement and Metabolomics-Based Analysis of <i>Lactobacillus delbrueckii</i> -Lactic Acid Production from Agro-Industrial Wastes by <i>Lactobacillus delbrueckii</i> Submitted to Adaptive Laboratory Evolution. <i>Journal of Agricultural and Food Chemistry</i> , 2020, 68, 7660-7669.	5.2	27
36	Proteomics reveals a therapeutic vulnerability via the combined blockade of APE1 and autophagy in lung cancer A549 cells. <i>BMC Cancer</i> , 2020, 20, 634.	2.6	13

#	ARTICLE	IF	CITATIONS
37	Rational Engineering of Multilayered Co <sub>3</sub> O <sub>4</sub> /ZnO Nanocatalysts through Chemical Transformations from Matryoshka-Type ZIFs. <i>Advanced Functional Materials</i> , 2019, 29, 1903774.	14.9	33
38	Electrochemiluminescence for Characterizing the Polymerization Process during Graphitic Carbon Nitride Synthesis. <i>ChemElectroChem</i> , 2019, 6, 3742-3746.	3.4	10
39	Gas-Mediated Cancer Bioimaging and Therapy. <i>ACS Nano</i> , 2019, 13, 10887-10917.	14.6	206
40	Using pH-Activable Carbon Nanoparticles as Cell Imaging Probes. <i>Micromachines</i> , 2019, 10, 568.	2.9	3
41	Graphitic Carbon Nitride Nanosheets as Co-reactants for Tris(2,2'-bipyridine)ruthenium(II) Electrochemiluminescence. <i>ChemElectroChem</i> , 2019, 6, 1673-1677.	3.4	8
42	Tris(2,2'-bipyridyl)ruthenium(II) Nanomaterial Co-reactant Electrochemiluminescence. <i>ChemElectroChem</i> , 2019, 6, 3878-3884.	3.4	20
43	Catalase-linked immunosorbent pressure assay for portable quantitative analysis. <i>Analyst</i> , 2019, 144, 4188-4193.	3.5	10
44	Dual-Responsive Alginate Hydrogels for Controlled Release of Therapeutics. <i>Molecules</i> , 2019, 24, 2089.	3.8	17
45	Self-Assembly of Functional Nucleic Acid-Based Colorimetric Competition Assay for the Detection of Immunoglobulin E. <i>Sensors</i> , 2019, 19, 2224.	3.8	5
46	Luminescent carbon nanodots based aptasensors for rapid detection of kanamycin residue. <i>Talanta</i> , 2019, 202, 452-459.	5.5	20
47	Carbon nanoparticles with oligonucleotide probes for a label-free sensitive antibiotic residues detection based on competitive analysis. <i>Scientific Reports</i> , 2019, 9, 3489.	3.3	8
48	Fabrication of Ultrathin 2D Cu <sub>2</sub> BDC Nanosheets and the Derived Integrated MOF Nanocomposites. <i>Advanced Functional Materials</i> , 2019, 29, 1806720.	14.9	123
49	Fabrication of Integrated Cu <sub>2</sub> O@HKUST-1@Au Nanocatalysts via Galvanic Replacements toward Alcohols Oxidation Application. <i>ACS Applied Materials &amp; Interfaces</i> , 2018, 10, 35234-35243.	8.0	44
50	Determination of the Lewis acidity of amide-AlCl <sub>3</sub> based ionic liquid analogues by combined in situ IR titration and NMR methods. <i>RSC Advances</i> , 2018, 8, 13248-13252.	3.6	12
51	A quantitative proteomic response of hepatocellular carcinoma Hep3B cells to danusertib, a pan-Aurora kinase inhibitor. <i>Journal of Cancer</i> , 2018, 9, 2061-2071.	2.5	8
52	Challenges and opportunities for siRNA-based cancer treatment. <i>Cancer Letters</i> , 2017, 387, 77-83.	7.2	82
53	Biochemical mechanism underlying hypertriglyceridemia and hepatic steatosis/hepatomegaly induced by acute schisandrin B treatment in mice. <i>Lipids in Health and Disease</i> , 2017, 16, 8.	3.0	5
54	Effect of Laparoscopic Peritoneal Lavage and Drainage and Continuous Venovenous Diahemofiltration on Severe Acute Pancreatitis. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2017, 27, 1145-1150.	1.0	9

#	ARTICLE	IF	CITATIONS
55	Collecting duct (pro)renin receptor targets ENaC to mediate angiotensin II-induced hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, F245-F253.	2.7	59
56	The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 511-530.	3.4	101
57	The combination of digoxin and GSK2606414 exerts synergistic anticancer activity against leukemia <i>in vitro</i> and <i>in vivo</i> . <i>BioFactors</i> , 2017, 43, 812-820.	5.4	17
58	Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells. <i>Scientific Reports</i> , 2017, 7, 5898.	3.3	40
59	Clinical and genomic responses to ultra-short course chemotherapy in spinal tuberculosis. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 1681-1688.	1.8	3
60	Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery. <i>Theranostics</i> , 2017, 7, 4071-4086.	10.0	70
61	Cerebral Reorganization in Subacute Stroke Survivors after Virtual Reality-Based Training: A Preliminary Study. <i>Behavioural Neurology</i> , 2017, 2017, 1-8.	2.1	39
62	The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/Erk/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma. <i>Journal of Cancer</i> , 2017, 8, 220-226.	2.5	29
63	Drug Design and Discovery: Principles and Applications. <i>Molecules</i> , 2017, 22, 279.	3.8	57
64	Alisertib promotes apoptosis and autophagy in melanoma through p38 MAPK-mediated aurora a signaling. <i>Oncotarget</i> , 2017, 8, 107076-107088.	1.8	19
65	Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells. <i>Current Cancer Drug Targets</i> , 2017, 17, 386-401.	1.6	20
66	Alisertib induces G/M arrest, apoptosis, and autophagy via PI3K/Akt/mTOR- and p38 MAPK-mediated pathways in human glioblastoma cells. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 845-873.	0.0	26
67	A proteomics-based investigation on the anticancer activity of alisertib, an Aurora kinase A inhibitor, in hepatocellular carcinoma Hep3B cells. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 3558-3572.	0.0	3
68	Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 4652-4672.	0.0	30
69	Alisertib Induces Cell Cycle Arrest, Apoptosis, Autophagy and Suppresses EMT in HT29 and Caco-2 Cells. <i>International Journal of Molecular Sciences</i> , 2016, 17, 41.	4.1	33
70	Computational Identification of the Paralogs and Orthologs of Human Cytochrome P450 Superfamily and the Implication in Drug Discovery. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1020.	4.1	23
71	A SILAC-Based Approach Elicits the Proteomic Responses to Vancomycin-Associated Nephrotoxicity in Human Proximal Tubule Epithelial HK-2 Cells. <i>Molecules</i> , 2016, 21, 148.	3.8	11
72	Molecular mechanisms for tumour resistance to chemotherapy. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2016, 43, 723-737.	1.9	304

#	ARTICLE	IF	CITATIONS
73	Effect of Somatostatin, Ulinastatin and Gabexate on the Treatment of Severe Acute Pancreatitis. American Journal of the Medical Sciences, 2016, 351, 506-512.	1.1	40
74	Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA). Journal of Epidemiology and Community Health, 2016, 70, 741-745.	3.7	138
75	A novel sensitive and selective electrochemical sensor based on molecularly imprinted polymer on a nanoporous gold leaf modified electrode for warfarin sodium determination. RSC Advances, 2016, 6, 43724-43731.	3.6	33
76	Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells. Cancer Letters, 2016, 382, 215-230.	7.2	32
77	An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 585-601.	1.9	37
78	Multifaceted ability of naturally occurring polyphenols against metastatic cancer. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 394-409.	1.9	24
79	Electrochemical hydrogen sulfide biosensors. Analyst, The, 2016, 141, 1185-1195.	3.5	143
80	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
81	Soluble (pro)renin receptor via $\beta$ -catenin enhances urine concentration capability as a target of liver X receptor. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1898-906.	7.1	83
82	Antidiuretic Action of Collecting Duct (Pro)Renin Receptor Downstream of Vasopressin and PGE2 Receptor EP4. Journal of the American Society of Nephrology: JASN, 2016, 27, 3022-3034.	6.1	67
83	Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. Hepatology International, 2016, 10, 501-510.	4.2	32
84	A Comparison of Non-Human Primate Cytochrome P450 2D Members and the Implication in Drug Discovery. Current Drug Metabolism, 2016, 17, 520-527.	1.2	2
85	miR-3646 promotes cell proliferation, migration, and invasion via regulating G2/M transition in human breast cancer cells. American Journal of Translational Research (discontinued), 2016, 8, 1659-77.	0.0	12
86	Dacomitinib, a new pan-EGFR inhibitor, is effective in killing ovarian cancer cells. Discovery Medicine, 2016, 22, 297-309.	0.5	5
87	An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides. Drug Design, Development and Therapy, 2015, 9, 33.	4.3	114
88	Schisandra chinensis regulates drug metabolizing enzymes and drug transporters via activation of $\text{Nrf2}$ -mediated signaling pathway. Drug Design, Development and Therapy, 2015, 9, 127.	4.3	20
89	Renal medullary (pro)renin receptor contributes to angiotensin II-induced hypertension in rats via activation of the local renin-angiotensin system. BMC Medicine, 2015, 13, 278.	5.5	63
90	Ectopic expression of <i>Hoxb4a</i> in hemangioblasts promotes hematopoietic development in early embryogenesis of zebrafish. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 1275-1286.	1.9	6

#	ARTICLE	IF	CITATIONS
91	A population-based study elicits a reverse correlation between age and overall survival in elderly patients with rectal carcinoma receiving adjuvant chemotherapy. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 752-765.	1.9	6
92	Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2839.	4.3	4
93	Hsa-microRNA-181a is a regulator of a number of cancer genes and a biomarker for endometrial carcinoma in patients: a bioinformatic and clinical study and the therapeutic implication. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1103.	4.3	35
94	Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach. <i>Drug Design, Development and Therapy</i> , 2015, 9, 937.	4.3	16
95	Novel targeting of PEGylated liposomes for codelivery of TGF- $\beta$ 1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4441.	4.3	15
96	Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2887.	4.3	20
97	High-throughput sequencing of 16S rDNA amplicons characterizes bacterial composition in cerebrospinal fluid samples from patients with purulent meningitis. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4417.	4.3	10
98	Repurposing paclitaxel for the treatment of fibrosis: indication discovery for existing drugs. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4869.	4.3	0
99	Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells. <i>Drug Design, Development and Therapy</i> , 2015, 9, 349.	4.3	22
100	Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells. <i>Drug Design, Development and Therapy</i> , 2015, 9, 993.	4.3	23
101	Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells. <i>Drug Design, Development and Therapy</i> , 2015, 9, 425.	4.3	43
102	The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1027.	4.3	26
103	A study on the hemocompatibility of dendronized chitosan derivatives in red blood cells. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2635.	4.3	24
104	Functional magnetic resonance imaging is a powerful approach to probing the mechanism of action of therapeutic drugs that act on the central nervous system. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3863.	4.3	2
105	Inflammation, cytokines, the IL-17/IL-6/STAT3/NF- $\kappa$ B axis, and tumorigenesis. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2941.	4.3	31
106	Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells. <i>Drug Design, Development and Therapy</i> , 2015, 9, 537.	4.3	35
107	Schisandrin B inhibits cell growth and induces cellular apoptosis and autophagy in mouse hepatocytes and macrophages: implications for its hepatotoxicity. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2001.	4.3	16
108	Lost expression of ADAMTS5 protein associates with progression and poor prognosis of hepatocellular carcinoma. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1773.	4.3	23

#	ARTICLE	IF	CITATIONS
109	Danuserib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2015, 16, 27228-27251.	4.1	45
110	Editorial for Special Issue on Herbal Medicines and Natural Products. <i>Medicines (Basel, Switzerland)</i> , 2015, 2, 328-330.	1.4	3
111	A bioinformatic and mechanistic study elicits the antifibrotic effect of ursolic acid through the attenuation of oxidative stress with the involvement of ERK, PI3K/Akt, and p38 MAPK signaling pathways in human hepatic stellate cells and rat liver. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3989.	4.3	37
112	Therapeutic effects of C-28 methyl ester of 2-cyano-3,12-dioxolean-1,9-dien-28-oic acid (CDDO-Me); Tj ETQq0 0 0 rgBT /Overlock 10 TF Development and Therapy, 2015, 9, 3163.	4.3	17
113	Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1511.	4.3	86
114	EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. <i>Theranostics</i> , 2015, 5, 1456-1472.	10.0	84
115	A computational and functional study elicits the ameliorating effect of the Chinese herbal formula Huo Luo Xiao Ling Dan on experimental ischemia-induced myocardial injury&nbsp;in rats via inhibition of&nbsp;apoptosis. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1063.	4.3	10
116	Cissus quadrangularis inhibits IL-1&beta; induced inflammatory responses on chondrocytes and alleviates bone deterioration in osteotomized rats&nbsp;via p38 MAPK signaling. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2927.	4.3	14
117	Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5511.	4.3	22
118	Controllable drug uptake and nongenomic response through estrogen-anchored cyclodextrin drug complex. <i>International Journal of Nanomedicine</i> , 2015, 10, 4717.	6.7	2
119	High-throughput sequencing of 16S rDNA amplicons characterizes bacterial composition in bronchoalveolar lavage fluid in patients with ventilator-associated pneumonia. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4883.	4.3	4
120	Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1555.	4.3	42
121	Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells. <i>Drug Design, Development and Therapy</i> , 2015, 9, 575.	4.3	47
122	Aptamer-Mediated Cancer Gene Therapy. <i>Current Gene Therapy</i> , 2015, 15, 109-119.	2.0	18
123	Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors. <i>Theranostics</i> , 2015, 5, 1083-1097.	10.0	147
124	Danuserib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in&nbsp;human gastric cancer AGS and NCI-N78 cells. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1293.	4.3	39
125	Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric&nbsp;cancer. <i>Drug Design, Development and Therapy</i> , 2015, 9, 901.	4.3	150
126	The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1627.	4.3	63



#	ARTICLE	IF	CITATIONS
127	Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1601.	4.3	75
128	Inhibition of mitotic&nbsp;Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. <i>Drug Design, Development and Therapy</i> , 2015, 9, 487.	4.3	32
129	Design and prediction of new anticoagulants as a selective Factor IXa inhibitor via three-dimensional quantitative structure-property relationships of&nbsp;amidinobenzothiophene derivatives. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1743.	4.3	0
130	MicroRNA Profiling Response to Acupuncture Therapy in Spontaneously Hypertensive Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-9.	1.2	20
131	Acupuncture and Oxidative Stress. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-1.	1.2	3
132	Acupuncture May Exert Its Therapeutic Effect through MicroRNA-339/Sirt2/NF<math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi>Î</mml:mi></mml:mrow></mml:math>B/FOXO1 Axis. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	18
133	Perspectives in Medicinal Chemistry:. <i>Current Topics in Medicinal Chemistry</i> , 2015, 16, 381-382.	2.1	32
134	Effects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice. <i>Drug Design, Development and Therapy</i> , 2015, 9, 923.	4.3	8
135	Multifunctional Iron Bound Lactoferrin and Nanomedicinal Approaches to Enhance Its Bioactive Functions. <i>Molecules</i> , 2015, 20, 9703-9731.	3.8	98
136	An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 1225-1238.	1.9	17
137	Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine. <i>Drug Metabolism Reviews</i> , 2015, 47, 470-519.	3.6	58
138	Systematic drug safety evaluation based on public genomic expression (Connectivity Map) data: Myocardial and infectious adverse reactions as application cases. <i>Biochemical and Biophysical Research Communications</i> , 2015, 457, 249-255.	2.1	18
139	Targeting Na<sup>+</sup>/K<sup>+</sup>â€translocating adenosine triphosphatase in cancer treatment. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 427-443.	1.9	57
140	New Perspectives on Dietary-derived Treatments and Food Safetyâ€”Antinomy in a New Era. <i>Critical Reviews in Food Science and Nutrition</i> , 2015, 55, 1836-1859.	10.3	5
141	Clinical Association Between Pharmacogenomics and Adverse Drug Reactions. <i>Drugs</i> , 2015, 75, 589-631.	10.9	57
142	Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies. <i>Drug Design, Development and Therapy</i> , 2015, 9, 841.	4.3	23
143	Multifunctional Poly(<sc>P</sc>-lactide)â€”Polyethylene Glycol-Grafted Graphene Quantum Dots for Intracellular MicroRNA Imaging and Combined Specific-Gene-Targeting Agents Delivery for Improved Therapeutics. <i>ACS Applied Materials &amp; Interfaces</i> , 2015, 7, 11015-11023.	8.0	110
144	Highly Sensitive and Selective MicroRNA Detection Based on DNA-Bio-Bar-Code and Enzyme-Assisted Strand Cycle Exponential Signal Amplification. <i>Analytical Chemistry</i> , 2015, 87, 4334-4340.	6.5	76

#	ARTICLE	IF	CITATIONS
145	Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 999-1024.	1.9	65
146	Graphene quantum dots induce apoptosis, autophagy, and inflammatory response via p38 mitogen-activated protein kinase and nuclear factor- $\kappa$ B mediated signaling pathways in activated THP-1 macrophages. <i>Toxicology</i> , 2015, 327, 62-76.	4.2	167
147	Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 125-138.	1.9	48
148	Dendritic and Langerhans cells respond to A $\beta$ peptides differently: implication for AD immunotherapy. <i>Oncotarget</i> , 2015, 6, 35443-35457.	1.8	3
149	Cancer stem cell targeted therapy: progress amid controversies. <i>Oncotarget</i> , 2015, 6, 44191-44206.	1.8	129
150	Nucleic Acid Aptamer-Guided Cancer Therapeutics and Diagnostics: the Next Generation of Cancer Medicine. <i>Theranostics</i> , 2015, 5, 23-42.	10.0	184
151	A SILAC-based proteomics elicits the molecular interactome of alisertib (MLN8237) in human erythroleukemia K562 cells. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 2442-61.	0.0	5
152	Brain-derived Neurotrophic Factor Signaling Pathway: Modulation by Acupuncture in Telomerase Knockout Mice. <i>Alternative Therapies in Health and Medicine</i> , 2015, 21, 36-46.	0.0	62
153	Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2449.	4.3	36
154	Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2517.	4.3	19
155	The Effect of Multiple Single Nucleotide Polymorphisms in the Folic Acid Pathway Genes on Homocysteine Metabolism. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	28
156	Synthesis and antibacterial activities of acylide derivatives bearing an aryl-tetrazolyl chain. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1515.	4.3	3
157	Coffee and caffeine potentiate the anti-amyloidogenic activity of melatonin via inhibition of A $\beta$ ; oligomerization and modulation of the Tau-mediated pathway in N2a/APP cells. <i>Drug Design, Development and Therapy</i> , 2014, 9, 241.	4.3	18
158	Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2075.	4.3	146
159	Matrix-induced autologous chondrocyte implantation for the treatment of chondral defects of the knees in Chinese patients. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2439.	4.3	11
160	Time and dose relationships between schisandrin B- and schisandrae fructus oil-induced hepatotoxicity and the associated elevations in hepatic and serum triglyceride levels in mice. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1429.	4.3	10
161	Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1745.	4.3	51
162	Editorial (Thematic Issue: Current Topics in Pharmacogenomics). <i>Recent Patents on Biotechnology</i> , 2014, 8, 109-109.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Mipu1 Protects H9c2 Myogenic Cells from Hydrogen Peroxide-Induced Apoptosis through Inhibition of the Expression of the Death Receptor Fas. <i>International Journal of Molecular Sciences</i> , 2014, 15, 18206-18220.	4.1	8
164	The Neuroprotective Role of Acupuncture and Activation of the BDNF Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2014, 15, 3234-3252.	4.1	49
165	Supplementation with the Extract of Schisandrae Fructus Pulp, Seed, or Their Combination Influences the Metabolism of Lipids and Glucose in Mice Fed with Normal and Hypercholesterolemic Diet. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-11.	1.2	8
166	Historical Perspective of Traditional Indigenous Medical Practices: The Current Renaissance and Conservation of Herbal Resources. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-20.	1.2	282
167	Structure of N-Terminal Sequence Asp-Ala-Glu-Phe-Arg-His-Asp-Ser of A $\beta$ <sup>2</sup> -Peptide with Phospholipase A2 from Venom of Andaman Cobra Sub-Species <i>Naja naja sagittifera</i> at 2.0 Å... Resolution. <i>International Journal of Molecular Sciences</i> , 2014, 15, 4221-4236.	4.1	2
168	Molecular Science for Drug Development and Biomedicine. <i>International Journal of Molecular Sciences</i> , 2014, 15, 20072-20078.	4.1	80
169	Electrochemical Sensors for Nitric Oxide Detection in Biological Applications. <i>Electroanalysis</i> , 2014, 26, 449-468.	2.9	65
170	Subcutaneous pharmacokinetics of the cardiac hormone vessel dilator. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 565-570.	1.9	0
171	Dietary pulp from Fructus Schisandra Chinensis supplementation reduces serum/hepatic lipid and hepatic glucose levels in mice fed a normal or high cholesterol/bile salt diet. <i>Lipids in Health and Disease</i> , 2014, 13, 46.	3.0	13
172	Adenosine as a probing tool for the mechanistic study of acupuncture treatment. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 933-939.	1.9	7
173	Inflammation and cancer stem cells. <i>Cancer Letters</i> , 2014, 345, 271-278.	7.2	105
174	MicroRNA-561 Promotes Acetaminophen-Induced Hepatotoxicity in HepG2 Cells and Primary Human Hepatocytes through Downregulation of the Nuclear Receptor Corepressor Dosage-Sensitive Sex-Reversal Adrenal Hypoplasia Congenital Critical Region on the X Chromosome, Gene 1 (DAX-1). <i>Drug Metabolism and Disposition</i> , 2014, 42, 44-61.	3.3	17
175	Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. <i>Cancer Letters</i> , 2014, 344, 239-259.	7.2	131
176	Risk factors for preterm premature rupture of membranes in Chinese women from urban cities. <i>International Journal of Gynecology and Obstetrics</i> , 2014, 127, 254-259.	2.3	30
177	Label-free and ultrasensitive microRNA detection based on novel molecular beacon binding readout and target recycling amplification. <i>Biosensors and Bioelectronics</i> , 2014, 53, 377-383.	10.1	58
178	Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. <i>Fundamental and Clinical Pharmacology</i> , 2014, 28, 551-582.	1.9	16
179	Prostaglandin E-Prostanoid $\text{EP}_4$ Receptor Mediates Angiotensin II-Induced (Pro)Renin Receptor Expression in the Rat Renal Medulla. <i>Hypertension</i> , 2014, 64, 369-377.	2.7	64
180	Xylometal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome P450 3a: a bioinformatic and animal study. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2555.	4.3	11

#	ARTICLE	IF	CITATIONS
181	Oxymatrine Improves Intestinal Epithelial Barrier Function Involving NF- $\kappa$ B-Mediated Signaling Pathway in CCl <sub>4</sub> -Induced Cirrhotic Rats. <i>PLoS ONE</i> , 2014, 9, e106082.	2.5	34
182	Modeling, Simulation, and Translation Framework for the Preclinical Development of Monoclonal Antibodies. <i>AAPS Journal</i> , 2013, 15, 551-558.	4.4	20
183	Genetic polymorphisms of 9 non-CODIS short tandem repeat loci in two ethnic minority populations in Southern China. <i>Forensic Science International: Genetics</i> , 2013, 7, e114-e115.	3.1	0
184	Multifunctional and multitargeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers. <i>Drug Discovery Today</i> , 2013, 18, 1292-1300.	6.4	57
185	Nitro-oleic acid protects against adriamycin-induced nephropathy in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, F1533-F1541.	2.7	49
186	RNA aptamers targeting cancer stem cell marker CD133. <i>Cancer Letters</i> , 2013, 330, 84-95.	7.2	157
187	Cyclodextrin-based targeting strategies for tumor treatment. <i>Drug Delivery and Translational Research</i> , 2013, 3, 364-374.	5.8	18
188	Synthesis and Biological Evaluation of Novel Folic Acid Receptor-Targeted, $\beta$ -Cyclodextrin-Based Drug Complexes for Cancer Treatment. <i>PLoS ONE</i> , 2013, 8, e62289.	2.5	47
189	New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-25.	1.2	378
190	mPGES-1-derived PGE <sub>2</sub> mediates dehydration natriuresis. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, F214-F221.	2.7	11
191	Aptamers as Theranostic Agents: Modifications, Serum Stability and Functionalisation. <i>Sensors</i> , 2013, 13, 13624-13637.	3.8	104
192	Prediction of Drug-Target Interactions for Drug Repositioning Only Based on Genomic Expression Similarity. <i>PLoS Computational Biology</i> , 2013, 9, e1003315.	3.2	58
193	The Effect of Somatostatin, Ulinastatin and <i>Salvia miltiorrhiza</i> on Severe Acute Pancreatitis Treatment. <i>American Journal of the Medical Sciences</i> , 2013, 346, 371-376.	1.1	31
194	Beclin 1 and nuclear factor- $\kappa$ Bp65 are upregulated in hepatocellular carcinoma. <i>Oncology Letters</i> , 2013, 5, 1813-1818.	1.8	13
195	Combining multiple serum biomarkers in tumor diagnosis: A clinical assessment. <i>Molecular and Clinical Oncology</i> , 2013, 1, 153-160.	1.0	22
196	Differential effects of selective and non-selective nitric oxide synthase inhibitors on the blood perfusion of ischemia-reperfused myocardium in dogs. <i>Medical Science Monitor Basic Research</i> , 2013, 19, 181-186.	2.6	5
197	Plumbagin induces the apoptosis of human tongue carcinoma cells through the mitochondria-mediated pathway. <i>Medical Science Monitor Basic Research</i> , 2013, 19, 228-236.	2.6	22
198	Mechanism of Kinect-based virtual reality training for motor functional recovery of upper limbs after subacute stroke. <i>Neural Regeneration Research</i> , 2013, 8, 2904-13.	3.0	49

#	ARTICLE	IF	CITATIONS
199	Metabolomic Response to Sorafenib Treatment in Human Hepatocellular Carcinoma Cells. <i>FASEB Journal</i> , 2013, 27, 663.7.	0.5	2
200	Modification of Rat Model of Sciatica Induced by Lumber Disc Herniation and the Anti-Inflammatory Effect of Osthole Given by Epidural Catheterization. <i>Pharmacology</i> , 2012, 90, 251-263.	2.2	12
201	Disposition Pathways and Pharmacokinetics of Herbal Medicines in Humans. <i>Current Medicinal Chemistry</i> , 2012, 17, 4072-4113.	2.4	41
202	Corn baked by burning coal triggered overexpression of osteopontin in hepatocytes of rats following fluorosis. <i>Toxicology and Industrial Health</i> , 2012, 28, 195-202.	1.4	10
203	Ligand- and Protein-Based Modeling Studies of the Inhibitors of Human Cytochrome P450 2D6 and a Virtual Screening for Potential Inhibitors from the Chinese Herbal Medicine, <i>Scutellaria baicalensis</i> (Huangqin, Baikal Skullcap). <i>Combinatorial Chemistry and High Throughput Screening</i> , 2012, 15, 36-80.	1.1	20
204	Pharmacophore, QSAR, and Binding Mode Studies of Substrates of Human Cytochrome P450 2D6 (CYP2D6) Using Molecular Docking and Virtual Mutations and an Application to Chinese Herbal Medicine Screening. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1640-1704.	1.6	34
205	Pharmacokinetics of Anticancer Materia Medica in Humans. <i>Evidence-based Anticancer Complementary and Alternative Medicine</i> , 2012, , 353-395.	0.1	0
206	Mechanism of reversal of high glucose-induced endothelial nitric oxide synthase uncoupling by tanshinone IIA in human endothelial cell line EA.hy926. <i>European Journal of Pharmacology</i> , 2012, 697, 97-105.	3.5	34
207	Efficacy of a Therapeutic Vaccine Using Mutated $\beta$ -amyloid Sensitized Dendritic Cells in Alzheimer's Mice. <i>Journal of Neuroimmune Pharmacology</i> , 2012, 7, 640-655.	4.1	13
208	Computational and <i>in vitro</i> studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2. <i>Xenobiotica</i> , 2012, 42, 238-255.	1.1	22
209	Interaction of Herbal Compounds with Biological Targets: A Case Study with Berberine. <i>Scientific World Journal</i> , The, 2012, 2012, 1-31.	2.1	47
210	Osthole, a herbal compound, alleviates nucleus pulposus-evoked nociceptive responses through the suppression of overexpression of acid-sensing ion channel 3 (ASIC3) in rat dorsal root ganglion. <i>Medical Science Monitor</i> , 2012, 18, BR229-BR236.	1.1	12
211	A comparative study of three ternary complexes prepared in different mixing orders of siRNA/redox-responsive hyperbranched poly (amido amine)/hyaluronic acid. <i>International Journal of Nanomedicine</i> , 2012, 7, 3837.	6.7	14
212	Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2012, 8, 399-414.	3.3	111
213	Therapeutic effect of transplanting magnetically labeled bone marrow stromal stem cells in a liver injury rat model with 70%-hepatectomy. <i>Medical Science Monitor</i> , 2012, 18, BR375-BR382.	1.1	9
214	Proteomic Response to Acupuncture Treatment in Spontaneously Hypertensive Rats. <i>PLoS ONE</i> , 2012, 7, e44216.	2.5	37
215	Cell Therapy: A Safe and Efficacious Therapeutic Treatment for Alzheimer's Disease in APP+PS1 Mice. <i>PLoS ONE</i> , 2012, 7, e49468.	2.5	13
216	Herb-Drug Interactions and Mechanistic and Clinical Considerations. <i>Current Drug Metabolism</i> , 2012, 13, 640-651.	1.2	112

#	ARTICLE	IF	CITATIONS
217	New perspectives on complementary and alternative medicine: an overview and alternative therapy. <i>Alternative Therapies in Health and Medicine</i> , 2012, 18, 20-36.	0.0	22
218	Cloning and characterization of a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase gene from <i>Salvia miltiorrhiza</i> involved in diterpenoid tanshinone accumulation. <i>Journal of Plant Physiology</i> , 2011, 168, 148-157.	3.5	127
219	Regulation of human pregnane X receptor and its target gene cytochrome P450 3A4 by Chinese herbal compounds and a molecular docking study. <i>Xenobiotica</i> , 2011, 41, 259-280.	1.1	50
220	Impaired fetal adrenal function in intrahepatic cholestasis of pregnancy. <i>Medical Science Monitor</i> , 2011, 17, CR265-CR271.	1.1	9
221	Determination of CA-125 levels in the serum, cervical and vaginal secretions, and endometrium in Chinese women with precancerous disease or endometrial cancer. <i>Medical Science Monitor</i> , 2011, 17, CR618-CR625.	1.1	12
222	NADPH oxidase-dependent formation of reactive oxygen species contributes to angiotensin II-induced epithelial-mesenchymal transition in rat peritoneal mesothelial cells. <i>International Journal of Molecular Medicine</i> , 2011, 28, 405-12.	4.0	13
223	Phenotype Prediction of Non-Synonymous Single Nucleotide Polymorphisms in Human ATP-Binding Cassette Transporter Genes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 94-114.	2.5	15
224	Herbal bioactivation, molecular targets and the toxicity relevance. <i>Chemico-Biological Interactions</i> , 2011, 192, 161-176.	4.0	81
225	Association between depression and malnutrition-inflammatory complex syndrome in patients with continuous ambulatory peritoneal dialysis. <i>International Urology and Nephrology</i> , 2011, 43, 875-882.	1.4	32
226	Pharmacokinetic Profiles of Anticancer Herbal Medicines in Humans and the Clinical Implications. <i>Current Medicinal Chemistry</i> , 2011, 18, 3190-3210.	2.4	21
227	Structural and Functional Properties of Human Multidrug Resistance Protein 1 (MRP1/ABCC1). <i>Current Medicinal Chemistry</i> , 2011, 18, 439-481.	2.4	120
228	Clinical Drugs Undergoing Polymorphic Metabolism by Human Cytochrome P450 2C9 and the Implication in Drug Development. <i>Current Medicinal Chemistry</i> , 2011, 18, 667-713.	2.4	41
229	Clinical Herbal Interactions with Conventional Drugs: From Molecules to Maladies. <i>Current Medicinal Chemistry</i> , 2011, 18, 4836-4850.	2.4	95
230	ADME Properties of Herbal Medicines in Humans: Evidence, Challenges and Strategies. <i>Current Pharmaceutical Design</i> , 2011, 17, 357-407.	1.9	53
231	Alterations of Maternal and Cord Plasma Hemostasis in Preeclampsia Before and After Delivery. <i>Hypertension in Pregnancy</i> , 2011, 30, 347-358.	1.1	8
232	Characterization of human cytomegalovirus UL145 and UL136 genes in low-passage clinical isolates from infected Chinese infants. <i>Medical Science Monitor</i> , 2011, 17, CR423-CR431.	1.1	11
233	Altered serum creatine kinase level and cardiac function in ischemia-reperfusion injury during percutaneous coronary intervention. <i>Medical Science Monitor</i> , 2011, 17, CR474-CR479.	1.1	10
234	Knowledge and use of folic acid for birth defect prevention among women of childbearing age in Shanghai, China: A prospective cross-sectional study. <i>Medical Science Monitor</i> , 2011, 17, PH87-PH92.	1.1	14

#	ARTICLE	IF	CITATIONS
235	Current and Future Therapeutic Targets of Rheumatoid Arthritis. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2011, 10, 92-120.	1.1	11
236	Current and future therapeutic targets of rheumatoid arthritis. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2011, 10, 92-120.	1.1	6
237	Pharmacokinetics and Disposition of Plant Natural Products in Humans and the Clinical and Toxicological Implications. Current Organic Chemistry, 2010, 14, 1833-1868.	1.6	3
238	Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development. Current Pharmaceutical Design, 2010, 16, 1313-1355.	1.9	19
239	Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species. Journal of Pharmacy and Pharmacology, 2010, 53, 463-471.	2.4	19
240	Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species. Journal of Pharmacy and Pharmacology, 2010, 54, 997-1003.	2.4	2
241	Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology, 2010, 278, 165-188.	4.2	103
242	Transcutaneous electrical nerve stimulation on acupoints relieves labor pain: A non-randomized controlled study. Chinese Journal of Integrative Medicine, 2010, 16, 234-238.	1.6	31
243	Mutations of the GATA4 and NKX2.5 genes in Chinese pediatric patients with non-familial congenital heart disease. Genetica, 2010, 138, 1231-1240.	1.1	62
244	Phenotype prediction of deleterious nonsynonymous single nucleotide polymorphisms in human alcohol metabolism-related genes: a bioinformatics study. Alcohol, 2010, 44, 425-438.	1.7	7
245	Urinary proteins from patients with nephrotic syndrome alters the signalling proteins regulating epithelial-mesenchymal transition. Nephrology, 2010, 15, 63-74.	1.6	19
246	Multidrug resistance-associated proteins and implications in drug development. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 115-120.	1.9	44
247	2009 Nobel Prize in physiology and medicine awarded for an enzyme in cancer. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 75-77.	1.9	1
248	This manuscript (Mengesha A, Wei JZ, Zhou S-F, Wei MQ. Clostridial spores to treat solid tumours -) of the senior author, who apologized for any inconvenience.. Current Gene Therapy, 2010, 10, 15-26.	2.0	13
249	Coronary Microcirculation Changes during Myocardial Stunning in Dogs. Cardiology, 2010, 117, 68-74.	1.4	5
250	Herbal Interactions with Anticancer Drugs: Mechanistic and Clinical Considerations. Current Medicinal Chemistry, 2010, 17, 1635-1678.	2.4	76
251	Modulators of Multidrug Resistance Proteins in the Management of Anticancer and Antimicrobial Drug Resistance and the Treatment of Inflammatory Diseases. Current Topics in Medicinal Chemistry, 2010, 10, 1732-1756.	2.1	26
252	Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metabolism Reviews, 2010, 42, 268-354.	3.6	220

#	ARTICLE	IF	CITATIONS
253	Suppression of tumor necrosis factor receptor associated factor (TRAF)-2 attenuates the proinflammatory and proliferative effect of aggregated IgG on rat renal mesangial cells. <i>Cytokine</i> , 2010, 49, 201-208.	3.2	12
254	Regulation of telomerase activity by apparently opposing elements. <i>Ageing Research Reviews</i> , 2010, 9, 245-256.	10.9	43
255	Effects of herbal products on the metabolism and transport of anticancer agents. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1195-1213.	3.3	56
256	Toxicology, Safety and Herbâ€“drug Interactions in Cancer Therapy. , 2010, , 293-340.		1
257	A Bioinformatics Approach for the Phenotype Prediction of Nonsynonymous Single Nucleotide Polymorphisms in Human Cytochromes P450. <i>Drug Metabolism and Disposition</i> , 2009, 37, 977-991.	3.3	42
258	Substrate Specificity, Inhibitors and Regulation of Human Cytochrome P450 2D6 and Implications in Drug Development. <i>Current Medicinal Chemistry</i> , 2009, 16, 2661-2805.	2.4	64
259	Prediction of Deleterious Functional Effects of Non-Synonymous Single Nucleotide Polymorphisms in Human Nuclear Receptor Genes Using a Bioinformatics Approach. <i>Drug Metabolism Letters</i> , 2009, 3, 242-286.	0.8	19
260	Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development. <i>Current Medicinal Chemistry</i> , 2009, 16, 4066-4218.	2.4	107
261	Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6. <i>Current Drug Metabolism</i> , 2009, 10, 730-753.	1.2	114
262	Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development. <i>Current Medicinal Chemistry</i> , 2009, 16, 3480-3675.	2.4	142
263	Activated nuclear factor- $\kappa$ B and increased tumor necrosis factor- $\alpha$ in atrial tissue of atrial fibrillation. <i>Scandinavian Cardiovascular Journal</i> , 2009, 43, 292-297.	1.2	79
264	GSK3 $\beta$ modulates PACAP-induced neuritogenesis in PC12 cells by acting downstream of Rap1 in a caveolae-dependent manner. <i>Cellular Signalling</i> , 2009, 21, 237-245.	3.6	20
265	Angiotensin-III upregulates Toll-like receptor 4 and enhances lipopolysaccharide-induced CD40 expression in rat peritoneal mesothelial cells. <i>Inflammation Research</i> , 2009, 58, 473-482.	4.0	32
266	Unbalanced translocation in an adult patient with premature ovarian failure and mental retardation detected by spectral karyotyping and arrayâ€“comparative genomic hybridization. <i>European Journal of Clinical Investigation</i> , 2009, 39, 729-737.	3.4	6
267	Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wortâ€“induced activity of cytochrome P450 3A4 enzyme. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 255-261.	2.4	41
268	Role of NAD(P)H oxidase in transforming growth factor- $\beta$ 1â€“induced monocyte chemoattractant protein-1 and interleukin-6 expression in rat renal tubular epithelial cells. <i>Nephrology</i> , 2009, 14, 302-310.	1.6	19
269	Prediction of Deleterious Non-synonymous Single-Nucleotide Polymorphisms of Human Uridine Diphosphate Glucuronosyltransferase Genes. <i>AAPS Journal</i> , 2009, 11, 469-80.	4.4	21
270	Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2. <i>AAPS Journal</i> , 2009, 11, 481-494.	4.4	183



#	ARTICLE	IF	CITATIONS
271	New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. <i>Drug Metabolism Reviews</i> , 2009, 41, 573-643.	3.6	152
272	Determinants and Prognostic Implications of Reperfusion Injury During Primary Percutaneous Coronary Intervention in Chinese Patients with Acute Myocardial Infarction. <i>Clinical Cardiology</i> , 2009, 32, 148-153.	1.8	4
273	Application of mechanism-based CYP inhibition for predicting drug-drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 579-605.	3.3	29
274	Activin inhibits telomerase activity in cancer. <i>Biochemical and Biophysical Research Communications</i> , 2009, 389, 668-672.	2.1	11
275	A cerebral functional imaging study by positron emission tomography in healthy volunteers receiving true or sham acupuncture needling. <i>Neuroscience Letters</i> , 2009, 452, 194-199.	2.1	29
276	Polymorphism of human cytochrome P450 enzymes and its clinical impact. <i>Drug Metabolism Reviews</i> , 2009, 41, 89-295.	3.6	671
277	Prediction of deleterious non-synonymous single nucleotide polymorphisms of genes related to ethanol-induced toxicity. <i>Toxicology Letters</i> , 2009, 187, 99-114.	0.8	6
278	Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance. <i>Clinical Pharmacokinetics</i> , 2009, 48, 689-723.	3.5	604
279	Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance. <i>Clinical Pharmacokinetics</i> , 2009, 48, 761-804.	3.5	306
280	New Insights into the Structural Features and Functional Relevance of Human Cytochrome P450 2C9. Part II. <i>Current Drug Metabolism</i> , 2009, 10, 1127-1150.	1.2	12
281	Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance. <i>Current Drug Metabolism</i> , 2009, 10, 781-834.	1.2	115
282	Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2. <i>Current Drug Metabolism</i> , 2009, 10, 713-729.	1.2	69
283	Structure, Function, Regulation and Polymorphism of Human Cytochrome P450 2A6. <i>Current Drug Metabolism</i> , 2009, 10, 754-780.	1.2	98
284	Human CYP2C8: Structure, Substrate Specificity, Inhibitor Selectivity, Inducers and Polymorphisms. <i>Current Drug Metabolism</i> , 2009, 10, 1009-1047.	1.2	80
285	New Insights into the Structural Features and Functional Relevance of Human Cytochrome P450 2C9. Part I. <i>Current Drug Metabolism</i> , 2009, 10, 1075-1126.	1.2	39
286	Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat. <i>Investigational New Drugs</i> , 2008, 26, 119-137.	2.6	4
287	Tanshinone IIB, a primary active constituent from <i>Salvia miltiorrhiza</i> , exerts neuroprotective effect via inhibition of neuronal apoptosis <i>in vitro</i> . <i>Phytotherapy Research</i> , 2008, 22, 846-850.	5.8	19
288	Rapid and simultaneous determination of tacrolimus (FK506) and diltiazem in human whole blood by liquid chromatography-tandem mass spectrometry: Application to a clinical drug-drug interaction study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 867, 111-118.	2.3	21

#	ARTICLE	IF	CITATIONS
289	Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme. <i>Journal of Controlled Release</i> , 2008, 129, 41-48.	9.9	70
290	Single Nucleotide Polymorphisms of the Pregnane X Receptor Gene in Han Chinese and a Comparison with Other Ethnic Populations. <i>Pharmacology</i> , 2008, 81, 350-354.	2.2	12
291	Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. <i>Xenobiotica</i> , 2008, 38, 802-832.	1.1	499
292	Induction of cytochrome P450s by terpene trilactones and flavonoids of the <i>Ginkgo biloba</i> extract EGb 761 in rats. <i>Xenobiotica</i> , 2008, 38, 465-481.	1.1	53
293	In vitro and in vivo neuroprotective effect and mechanisms of glabridin, a major active isoflavan from <i>Glycyrrhiza glabra</i> (licorice). <i>Life Sciences</i> , 2008, 82, 68-78.	4.3	118
294	Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose. <i>Archives of Biochemistry and Biophysics</i> , 2008, 475, 128-134.	3.0	84
295	The C-terminus of PRK2/PKN <sup>3</sup> is required for optimal activation by RhoA in a GTP-dependent manner. <i>Archives of Biochemistry and Biophysics</i> , 2008, 479, 170-178.	3.0	10
296	Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 69, 899-907.	4.3	65
297	Differential chemokine expression in tubular cells in response to urinary proteins from patients with nephrotic syndrome. <i>Cytokine</i> , 2008, 42, 222-233.	3.2	14
298	Preclinical factors affecting the pharmacokinetic behaviour of tanshinone IIA, an investigational new drug isolated from <i>Salvia miltiorrhiza</i> for the treatment of ischaemic heart diseases. <i>Xenobiotica</i> , 2008, 38, 185-222.	1.1	51
299	Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4. <i>Current Drug Metabolism</i> , 2008, 9, 310-322.	1.2	550
300	Induction of Cytochrome P450 3A by the Ginkgo biloba Extract and Bilobalides in Human and Rat Primary Hepatocytes. <i>Drug Metabolism Letters</i> , 2008, 2, 60-66.	0.8	36
301	Potential Strategies for Minimizing Mechanism-Based Inhibition of Cytochrome P450 3A4. <i>Current Pharmaceutical Design</i> , 2008, 14, 990-1000.	1.9	44
302	Identification of Apolipoprotein E Guangzhou (Arginine 150 Proline), a New Variant Associated with Lipoprotein Glomerulopathy. <i>American Journal of Nephrology</i> , 2008, 28, 347-353.	3.1	34
303	Human Leukocyte Antigen <i>DRB1</i> Alleles Predict Risk and Disease Progression of Immunoglobulin A Nephropathy in Han Chinese. <i>American Journal of Nephrology</i> , 2008, 28, 684-691.	3.1	24
304	Upregulation of Rat Renal Cortical Organic Anion Transporter (OAT1 and OAT3) Expression in Response to Ischemia/Reperfusion Injury. <i>American Journal of Nephrology</i> , 2008, 28, 772-783.	3.1	15
305	Prevalence and risk factors associated with chronic kidney disease in an adult population from southern China. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 1205-1212.	0.7	125
306	Structure, Function and Polymorphism of Human Cytosolic Sulfotransferases. <i>Current Drug Metabolism</i> , 2008, 9, 99-105.	1.2	137

#	ARTICLE	IF	CITATIONS
307	Pharmacokinetic characterization of hydroxypropyl- $\beta$ -cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen ( <i>Salvia miltiorrhiza</i> ). <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 1419-1427.	1.4	10
308	Placental Drug Disposition and Its Clinical Implications. <i>Current Drug Metabolism</i> , 2008, 9, 106-121.	1.2	23
309	Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development. <i>Current Medicinal Chemistry</i> , 2008, 15, 1981-2039.	2.4	330
310	Ethanol exposure induces differential microRNA and target gene expression and teratogenic effects which can be suppressed by folic acid supplementation. <i>Human Reproduction</i> , 2008, 24, 562-579.	0.9	214
311	Chemistry and Bioactivity of Flos Magnoliae, A Chinese Herb for Rhinitis and Sinusitis. <i>Current Medicinal Chemistry</i> , 2008, 15, 1616-1627.	2.4	53
312	Role of P-glycoprotein in the Transport of Tanshinone I, One Active Triterpenoid from <i>Salvia miltiorrhiza</i> . <i>Drug Metabolism Letters</i> , 2008, 2, 223-230.	0.8	14
313	Clinical Pharmacogenetics and Potential Application in Personalized Medicine. <i>Current Drug Metabolism</i> , 2008, 9, 738-784.	1.2	196
314	An Update on Clinical Drug Interactions with the Herbal Antidepressant St. Johns wort. <i>Current Drug Metabolism</i> , 2008, 9, 394-409.	1.2	80
315	Clinical Drugs that Interact with St. Johns Wort and mplication in Drug Development. <i>Current Pharmaceutical Design</i> , 2008, 14, 1723-1742.	1.9	91
316	Role of P-glycoprotein in the Intestinal Absorption of Glabridin, an Active Flavonoid from the Root of <i>Glycyrrhiza glabra</i> . <i>Drug Metabolism and Disposition</i> , 2007, 35, 539-553.	3.3	76
317	Metabolic Activation of Herbal and Dietary Constituents and Its Clinical and Toxicological Implications: An Update. <i>Current Drug Metabolism</i> , 2007, 8, 526-553.	1.2	126
318	A Pharmacogenetic Study of Pregnane X Receptor (NR1I2) in Han Chinese. <i>Current Drug Metabolism</i> , 2007, 8, 778-786.	1.2	20
319	A Mechanistic Study on Altered Pharmacokinetics of Irinotecan by St. Johns Wort. <i>Current Drug Metabolism</i> , 2007, 8, 157-171.	1.2	30
320	Transport of Cryptotanshinone, a Major Active Triterpenoid in <i>Salvia miltiorrhiza</i> Bunge Widely Used in the Treatment of Stroke and Alzheimers Disease, Across the Blood-Brain Barrier. <i>Current Drug Metabolism</i> , 2007, 8, 365-377.	1.2	87
321	Role of ATP-binding cassette drug transporters in the intestinal absorption of tanshinone IIB, one of the major active diterpenoids from the root of <i>Salvia miltiorrhiza</i> . <i>Xenobiotica</i> , 2007, 37, 375-415.	1.1	23
322	Role of P-Glycoprotein in the Intestinal Absorption of Tanshinone IIA, a Major Active Ingredient in the Root of <i>Salvia miltiorrhiza</i> Bunge. <i>Current Drug Metabolism</i> , 2007, 8, 325-340.	1.2	74
323	Multidrug Resistance Associated Proteins as Determining Factors of Pharmacokinetics and Pharmacodynamics of Drugs. <i>Current Drug Metabolism</i> , 2007, 8, 787-802.	1.2	60
324	Involvement of P-glycoprotein and Multidrug Resistance Associated Protein 1 in the Transport of Tanshinone IIB, a Primary Active Diterpenoid Quinone from the Roots of <i>Salvia miltiorrhiza</i> , Across the Blood-Brain Barrier. <i>Drug Metabolism Letters</i> , 2007, 1, 205-217.	0.8	13

#	ARTICLE	IF	CITATIONS
325	Effect of Recombinant Human Thymosin- $\hat{1}$ , an Immuno-Modulating Peptide with 28 Amino Acids, on the Activity of Cytochrome P450s. <i>Drug Metabolism Letters</i> , 2007, 1, 199-204.	0.8	6
326	Role of P-glycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of <i>Salvia miltiorrhiza</i> Bunge, across the blood-brain barrier. <i>Xenobiotica</i> , 2007, 37, 635-678.	1.1	40
327	Pharmacogenetics of Oxazaphosphorines and its Clinical Implications. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2007, 5, 143-156.	0.3	0
328	Clinical Significance of Thiopurine S-Methyltransferase Gene Polymorphisms. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2007, 5, 103-115.	0.3	3
329	Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 687-710.	2.0	317
330	Tanshinone IIB, a primary active constituent from <i>Salvia miltiorrhiza</i> , exhibits neuro-protective activity in experimentally stroked rats. <i>Neuroscience Letters</i> , 2007, 417, 261-265.	2.1	43
331	HLA Polymorphisms and Genetic Markers for Traditional Chinese Medicine. <i>Journal of Alternative and Complementary Medicine</i> , 2007, 13, 401-402.	2.1	0
332	A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to bioequivalence studies. <i>Biomedical Chromatography</i> , 2007, 21, 1045-1051.	1.7	20
333	Simultaneous and rapid quantitation of benazepril and benazeprilat in human plasma by high performance liquid chromatography with ultraviolet detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007, 44, 224-230.	2.8	10
334	Simultaneous determination of irinotecan (CPT-11) and SN-38 in tissue culture media and cancer cells by high performance liquid chromatography: Application to cellular metabolism and accumulation studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 850, 575-580.	2.3	25
335	Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 852, 534-544.	2.3	52
336	High performance liquid chromatography with ultraviolet detection for the determination of SYUIQ-5, a novel telomerase inhibitor for cancer therapy: Application to an enzyme kinetic study in rat liver microsomes. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 854, 332-337.	2.3	2
337	Determination of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase, in human Caco-2 monolayers by high performance liquid chromatography with ultraviolet detection: Application to a trans-epithelial transport study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 854, 320-327.	2.3	5
338	Evidence for Coexistence of Three $\hat{2}$ -Adrenoceptor Subtypes in Human Peripheral Lymphocytes. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 654-658.	4.7	24
339	Identification of drugs that interact with herbs in drug development. <i>Drug Discovery Today</i> , 2007, 12, 664-673.	6.4	138
340	Reply to Dr. Birdsall's letter to the editor. <i>Toxicology and Applied Pharmacology</i> , 2007, 220, 109-110.	2.8	1
341	Determination of Cryptotanshinone, a Major Active Component in <i>Salvia miltiorrhiza</i> , in Caco-2 Monolayers by HPLC with UV Detection. <i>Chromatographia</i> , 2007, 66, 577-582.	1.3	0
342	Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 555-563.	1.9	44

#	ARTICLE	IF	CITATIONS
343	Role of P-glycoprotein in Limiting the Brain Penetration of Glabridin, An Active Isoflavan from the Root of <i>Glycyrrhiza glabra</i> . <i>Pharmaceutical Research</i> , 2007, 24, 1668-1690.	3.5	39
344	The Prophylactic Effects of Chinese Herbal Extract, "Braintone"™, on Stroked Wistar Rats. , 2007, , 365-376.		0
345	ERCC1 and non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2007, 356, 2540; author reply 2540-1.	27.0	2
346	Proteomic Analysis of Hypertrophied Myocardial Protein Patterns in Renovascularly Hypertensive and Spontaneously Hypertensive Rats. <i>Journal of Proteome Research</i> , 2006, 5, 2901-2908.	3.7	48
347	Monitoring drug-protein interaction. <i>Clinica Chimica Acta</i> , 2006, 365, 9-29.	1.1	35
348	Determination of intra-ethnic differences in the polymorphisms of thiopurine S-methyltransferase in Chinese. <i>Clinica Chimica Acta</i> , 2006, 365, 337-341.	1.1	25
349	Rapid determination of common mutations in glutathione S-transferase gene by PCR-based methods in healthy Chinese. <i>Clinica Chimica Acta</i> , 2006, 364, 205-208.	1.1	21
350	Involvement of the GC-rich sequence and specific proteins (Sp1/Sp3) in the basal transcription activity of neurogranin gene. <i>Biochemical and Biophysical Research Communications</i> , 2006, 345, 124-132.	2.1	10
351	Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. <i>International Immunopharmacology</i> , 2006, 6, 499-508.	3.8	105
352	Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 457-472.	2.4	71
353	Intra- and Inter-ethnic Differences in the Allele Frequencies of Cytochrome P450 2B6 Gene in Chinese. <i>Pharmaceutical Research</i> , 2006, 23, 1983-1990.	3.5	45
354	Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 28, 77-85.	4.0	58
355	Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 29, 14-21.	4.0	35
356	St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. <i>Toxicology and Applied Pharmacology</i> , 2006, 216, 225-237.	2.8	59
357	Clinical Pharmacology of Cyclophosphamide and Ifosfamide. <i>Current Drug Therapy</i> , 2006, 1, 55-84.	0.3	83
358	Topotecan Is a Substrate for Multidrug Resistance Associated Protein 4. <i>Current Drug Metabolism</i> , 2006, 7, 105-118.	1.2	75
359	Drug-Herb Interactions: Eliminating Toxicity with Hard Drug Design. <i>Current Pharmaceutical Design</i> , 2006, 12, 4649-4664.	1.9	66
360	Bioactivation and Hepatotoxicity of Nitroaromatic Drugs. <i>Current Drug Metabolism</i> , 2006, 7, 715-727.	1.2	166

#	ARTICLE	IF	CITATIONS
361	Reversal of Resistance to Oxazaphosphorines. <i>Current Cancer Drug Targets</i> , 2006, 6, 385-407.	1.6	14
362	Induction of Propranolol Metabolism by Ginkgo biloba Extract EGb 761 in Rats. <i>Current Drug Metabolism</i> , 2006, 7, 577-587.	1.2	33
363	Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide. <i>Current Drug Metabolism</i> , 2006, 7, 431-454.	1.2	10
364	A Mechanistic Study on Reduced Toxicity of Irinotecan by Coadministered Thalidomide, a Tumor Necrosis Factor- $\alpha$ Inhibitor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 82-104.	2.5	33
365	The Last 10 Amino Acid Residues beyond the Hydrophobic Motif Are Critical for the Catalytic Competence and Function of Protein Kinase C $\beta$ . <i>Journal of Biological Chemistry</i> , 2006, 281, 30768-30781.	3.4	18
366	A Mechanistic Study of the Intestinal Absorption of Cryptotanshinone, the Major Active Constituent of <i>Salvia miltiorrhiza</i> . <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 1285-1294.	2.5	86
367	Small Interfering RNA-Mediated Silencing of Cytochrome P450 3A4 Gene. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1650-1657.	3.3	13
368	Determination of thalidomide by high performance liquid chromatography: Plasma pharmacokinetic studies in the rat. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 39, 299-304.	2.8	16
369	INHIBITION OF HUMAN CYP1A2 OXIDATION OF 5,6-DIMETHYL-XANTHENONE-4-ACETIC ACID BY ACRIDINES: A MOLECULAR MODELLING STUDY. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2005, 32, 633-639.	1.9	7
370	Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 24, 513-524.	4.0	29
371	Antitumor and neurotoxic effects of novel harmine derivatives and structure-activity relationship analysis. <i>International Journal of Cancer</i> , 2005, 114, 675-682.	5.1	134
372	Multidrug resistance proteins (MRPs) and implication in drug development. <i>Drug Development Research</i> , 2005, 64, 1-18.	2.9	29
373	Transport of thalidomide by the human intestinal Caco-2 monolayers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2005, 30, 49-61.	1.6	16
374	Significant Intestinal Excretion, One Source of Variability in Pharmacokinetics of COL-3, a Chemically Modified Tetracycline. <i>Pharmaceutical Research</i> , 2005, 22, 397-404.	3.5	10
375	St. John's Wort Modulates the Toxicities and Pharmacokinetics of CPT-11 (Irinotecan) in Rats. <i>Pharmaceutical Research</i> , 2005, 22, 902-914.	3.5	40
376	Human Multidrug Resistance Associated Protein 4 Confers Resistance to Camptothecins. <i>Pharmaceutical Research</i> , 2005, 22, 1837-1853.	3.5	127
377	Prediction of herb-drug metabolic interactions: a simulation study. <i>Phytotherapy Research</i> , 2005, 19, 464-471.	5.8	19
378	Determination of adefovir in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. <i>Rapid Communications in Mass Spectrometry</i> , 2005, 19, 2911-2917.	1.5	20

#	ARTICLE	IF	CITATIONS
379	Antitumor Activity and Underlying Mechanisms of Ganopoly, The Refined Polysaccharides Extracted from Ganoderma Lucidum, in Mice. Immunological Investigations, 2005, 34, 171-198.	2.0	51
380	An Interethnic Comparison of Polymorphisms of the Genes Encoding Drug-Metabolizing Enzymes and Drug Transporters: Experience in Singapore. Drug Metabolism Reviews, 2005, 37, 327-378.	3.6	104
381	Antimicrobial Activity of the Medicinal Mushroom Ganoderma. Food Reviews International, 2005, 21, 211-229.	8.4	54
382	Antitumor Activity and Underlying Mechanisms of Ganopoly, The Refined Polysaccharides Extracted from Ganoderma Lucidum, in Mice. Immunological Investigations, 2005, 34, 171-198.	2.0	68
383	Protective Effect of Ganoderma (a Mushroom with Medicinal Properties) Against Various Liver Injuries. Food Reviews International, 2005, 21, 27-52.	8.4	9
384	Metabolism and Transport of Oxazaphosphorines and the Clinical Implications. Drug Metabolism Reviews, 2005, 37, 611-703.	3.6	158
385	Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance. Drug Metabolism Reviews, 2005, 37, 41-213.	3.6	257
386	Insights into oxazaphosphorine resistance and possible approaches to its circumvention. Drug Resistance Updates, 2005, 8, 271-297.	14.4	44
387	Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs. Clinical Pharmacokinetics, 2005, 44, 279-304.	3.5	419
388	Herb-Drug Interactions. Drugs, 2005, 65, 1239-1282.	10.9	520
389	Human Multidrug Resistance Associated Protein 4 Confers Resistance to Camptothecins. Pharmaceutical Research, 2005, 22, 1837.	3.5	6
390	Approximate entropy of fetal heart rate variability as a predictor of fetal distress in women at term pregnancy. Acta Obstetrica Et Gynecologica Scandinavica, 2005, 84, 837-843.	2.8	3
391	An Interethnic Comparison of Polymorphisms of the Genes Encoding Drug-Metabolizing Enzymes and Drug Transporters: Experience in Singapore. Drug Metabolism Reviews, 2005, 37, 327-378.	3.6	43
392	Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance. Drug Metabolism Reviews, 2005, 37, 41-213.	3.6	20
393	Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Therapeutics and Clinical Risk Management, 2005, 1, 3-13.	2.0	152
394	Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4. Current Drug Metabolism, 2004, 5, 415-442.	1.2	156
395	Phenotyping and genotyping study of thiopurine S-methyltransferase in healthy Chinese children: A comparison of Han and Yao ethnic groups. British Journal of Clinical Pharmacology, 2004, 58, 163-168.	2.4	39
396	Gene mutation of thiopurine S-methyltransferase in Uyгур Chinese. European Journal of Clinical Pharmacology, 2004, 60, 1-3.	1.9	11

#	ARTICLE	IF	CITATIONS
397	Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 809, 87-97.	2.3	10
398	Immunomodulating Activities of Ganoderma, a Mushroom with Medicinal Properties. <i>Food Reviews International</i> , 2004, 20, 123-161.	8.4	58
399	Pharmacokinetic Interactions of Drugs with St John's Wort. <i>Journal of Psychopharmacology</i> , 2004, 18, 262-276.	4.0	228
400	Herbal bioactivation: The good, the bad and the ugly. <i>Life Sciences</i> , 2004, 74, 935-968.	4.3	207
401	Herbal Modulation of P-glycoprotein. <i>Drug Metabolism Reviews</i> , 2004, 36, 57-104.	3.6	355
402	Predicting Pharmacokinetic Herb-Drug Interactions. <i>Drug Metabolism and Drug Interactions</i> , 2004, 20, 143-158.	0.3	30
403	Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. <i>Biochemical Pharmacology</i> , 2003, 65, 109-120.	4.4	12
404	Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. <i>Biochemical Pharmacology</i> , 2003, 65, 1853-1865.	4.4	6
405	Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 785, 165-173.	2.3	20
406	Separation and detection methods for covalent drug-protein adducts. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 797, 63-90.	2.3	47
407	Interactions of Herbs with Cytochrome P450. <i>Drug Metabolism Reviews</i> , 2003, 35, 35-98.	3.6	349
408	Cancer Prevention and Treatment by Ganoderma, a Mushroom with Medicinal Properties. <i>Food Reviews International</i> , 2003, 19, 275-325.	8.4	53
409	Effects of Ganopoly® (AGanoderma lucidum Polysaccharide Extract) on the Immune Functions in Advanced-Stage Cancer Patients. <i>Immunological Investigations</i> , 2003, 32, 201-215.	2.0	233
410	Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo. <i>Xenobiotica</i> , 2002, 32, 87-107.	1.1	23
411	PREDICTING PHARMACOKINETICS AND DRUG INTERACTIONS IN PATIENTS FROM IN VITRO AND IN VIVO MODELS: THE EXPERIENCE WITH 5,6-DIMETHYLXANTHENE-4-ACETIC ACID (DMXAA), AN ANTI-CANCER DRUG ELIMINATED MAINLY BY CONJUGATION. <i>Drug Metabolism Reviews</i> , 2002, 34, 751-790.	3.6	18
412	Thalidomide in Cancer Treatment. <i>Drugs and Aging</i> , 2002, 19, 85-100.	2.7	17
413	Mechanism of the antiulcerogenic effect of Ganoderma lucidum polysaccharides on indomethacin-induced lesions in the rat. <i>Life Sciences</i> , 2002, 72, 731-745.	4.3	69
414	6-methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2002, 27, 179-183.	1.6	12



#	ARTICLE	IF	CITATIONS
415	Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 49, 126-132.	2.3	10
416	Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 776, 231-236.	2.3	2
417	5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. <i>Investigational New Drugs</i> , 2002, 20, 281-295.	2.6	42
418	In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 319-326.	2.3	21
419	Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography. <i>Biomedical Applications</i> , 2001, 757, 343-348.	1.7	8
420	Identification and reactivity of the major metabolite ( $\beta$ -1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans. <i>Xenobiotica</i> , 2001, 31, 277-293.	1.1	32
421	Role of Apoptosis in Cancer Resistance to Chemotherapy. , 0, , .		22